ImmuCell Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
ImmuCell Corporation (ICCC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 54.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-30
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 55.00%, a 5.77% increase year-over-year.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 52.00%, a 4.00% increase year-over-year.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 52.00%.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 50.00%, a 0.00% change year-over-year.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 54.00%, a 3.85% increase from fiscal 2024.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 52.00%, a 3.70% decline from fiscal 2023.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 54.00%, a 1.89% increase from fiscal 2022.
- ImmuCell Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 53.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 54.00% 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 55.00% 10-Q · filed 2025-11-13 | 53.00% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 52.00% 10-Q · filed 2025-08-14 | 52.00% 10-Q · filed 2025-08-14 | ||
| 2024-12-31 | 52.00% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 52.00% 10-Q · filed 2025-11-13 | 51.00% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 50.00% 10-Q · filed 2025-08-14 | 50.00% 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 52.00% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 54.00% 10-K · filed 2025-03-28 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-13 | 54.00% 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | 50.00% 10-Q · filed 2024-08-13 | 54.00% 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 55.00% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 53.00% 10-K · filed 2024-04-01 | |||
| 2022-09-30 | 52.00% 10-Q · filed 2023-11-13 | 53.00% 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |